Evidence map›Paper›PMID 41193251›Full record

ArticlemAbs2025

Integrating computational simulation and high-throughput screening for the development of robust ultra-high concentration formulation of IgG1 antibody.

Chen Lyu, Shuyan Lu, Yiqiu Yin, Hongling Li, Dahui Xing, Yanjie Lu, Shujing Zheng, Qiuyu Zhang, Lingyu Gao, Shuxian Xu and 4 more

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chen LyuDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Shuyan LuDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Yiqiu YinDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Hongling LiDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Dahui XingDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Yanjie LuDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Shujing ZhengDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Qiuyu ZhangDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Lingyu GaoDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Shuxian XuDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Qian ZouDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Feng LiuDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Jinliang ZhangDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.
Yun KangDrug Product & Device Development Center, Genescience Pharmaceuticals Co., Ltd., Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-viscosity monoclonal antibody (mAb) formulations impede injection, complicate manufacturing, and may affect drug stability and patient outcomes. Nevertheless, these issues can be effectively mitigated through the judicious selection of appropriate excipients and meticulous formulation optimization. In this study, we present an innovative approach that integrates computational simulation with high-throughput screening to enhance the efficiency of high-concentration mAb formulation development. Specifically, we introduce

Indexed as

Antibodies, MonoclonalComputer SimulationDrug CompoundingHigh-Throughput Screening AssaysImmunoglobulin GChemistry, PharmaceuticalDrug StabilityExcipientsHumansProtein StabilityViscosityAntibodies, MonoclonalExcipientsImmunoglobulin GFormulation developmentHigh-throughput screeningHigh-viscosity mAbIn silico modeling

Identifiers

PMID41193251
PMCPMC12599885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.